Characterization of noncovalent complexes of antimalarial agents of the artemisinin-type and FE(III)-Heme by electrospray mass spectrometry and collisional activation tandem mass spectrometry  by Pashynska, Vlada A. et al.
Characterization of Noncovalent Complexes
of Antimalarial Agents of the Artemisinin-Type
and FE(III)-Heme by Electrospray Mass
Spectrometry and Collisional Activation
Tandem Mass Spectrometry
Vlada A. Pashynska,* Hilde Van den Heuvel, and Magda Claeys
Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium
Marina V. Kosevich
Verkin Institute for Low Temperature Physics and Engineering, National Academy of Sciences of Ukraine,
Kharkov, Ukraine
In this study, we demonstrate, using electrospray ionization mass spectrometry (ESI-MS) and
collision-induced dissociation tandem mass spectrometry (ESI-MS/CID/MS), that stable
noncovalent complexes can be formed between Fe(III)-heme and antimalarial agents, i.e.,
quinine, artemisinin, and the artemisinin derivatives, dihydroartemisinin, - and -arte-
mether, and -arteether. Differences in the binding behavior of the examined drugs with
Fe(III)-heme and the stability of the drug-heme complexes are demonstrated. The results show
that all tested antimalarial agents form a drug-heme complex with a 1:1 stoichiometry but that
quinine also results in a second complex with the heme dimer. ESI-MS performed on mixtures
of pairs of various antimalarial agents with heme indicate that quinine binds preferentially to
Fe(III)-heme, while ESI-MS/CID/MS shows that the quinine-heme complex is nearly two
times more stable than the complexes formed between heme and artemisinin or its derivatives.
Moreover, it is found that dihydroartemisinin, the active metabolite of the artemisinin-type
drugs in vivo, results in a Na-containing heme-drug complex, which is as stable as the
heme-quinine complex. The efficiency of drug-heme binding of artemisinin derivatives is
generally lower and the decomposition under CID higher compared with quinine, but these
parameters are within the same order of magnitude. These results suggest that the efficiency
of antimalarial agents of the artemisinin-type to form noncovalent complexes with Fe(III)-
heme is comparable with that of the traditional antimalarial agent, quinine. Our study
illustrates that electrospray ionization mass spectrometry and collision-induced dissociation
tandem mass spectrometry are suitable tools to probe noncovalent interactions between heme
and antimalarial agents. The results obtained provide insights into the underlying molecular
modes of action of the traditional antimalarial agent quinine and of the antimalarials of the
artemisinin-type which are currently used to treat severe or multidrug-resistant
malaria. (J Am Soc Mass Spectrom 2004, 15, 1181–1190) © 2004 American Society for Mass
SpectrometryThe major problem in the treatment of malaria isthe increasing resistance of the malarial parasites,e.g., Plasmodium falciparum, to the commonly
used antimalarial drugs, i.e., quinolines [1–3]. The
quinolines, particularly quinine, chloroquine, and mef-
loquine, have been the basic drugs for treatment of
malaria during the past 50 years and are still widely
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quinolines is due to inhibition of the polymerization
pathway of free heme, which is released inside the food
vacuole of the parasite after hemoglobin proteolysis
and is toxic to the parasite owing to its oxidative
damage to cell membranes and other biomolecules [4].
It has been demonstrated that the underlying molecular
mechanism of the quinolines is based on association of
the drugs with Fe(III)-heme and heme polymer, i.e.,
noncovalent binding, which can interfere with the heme
polymerization pathway [5–7]. The polymerized heme
accumulates in the form of an insoluble, microcrystal-
line black-brown pigment called hemozoin or the ma-r Inc. Received August 28, 2003
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and is not a polymer as previously thought but a
repeating array of coordinated dimers, bound through
reciprocal iron(III)-carboxylate bonds to one of the
propionic side chains of each porphyrin and held to-
gether in a crystalline matrix by hydrogen bonding
interactions [8]. Because the polymerization pathway is
unique to the malarial parasite, it offers an attractive
target for the design of new antimalarials.
The first antimalarial compound to be discovered,
which also served as the lead compound for synthetic
antimalarials of the quinoline-type, was the alkaloid
quinine isolated from Chinchona bark (for a historical
account, see [9]). Many other leads for potential new
antimalarials have been characterized since then, and
several of them have been isolated from medicinal
plants. One of these plants is Artemisia annua, which has
been used in Chinese traditional medicine (Quing-
haosu) for more than two thousand years as a herbal
anti-fever remedy [1, 10]. In 1969, a promising lead
compound, artemisinin, was isolated from Artemisia
annua by the Chinese scientist Zhenxing Wei [10], and
since then a number of artemisinin derivatives have
been synthesized and tested. Artemisinin and its deriv-
atives are currently successfully used to treat severe or
multidrug-resistant Plasmodium falciparum malaria, in-
cluding cerebral malaria [1, 11]. However, the exact
molecular mechanisms of drugs of the artemisinin-type
are still not properly understood and are, therefore, a
current topic of active investigation [12]. Artemisinin is
a sesquiterpene lactone bearing an endoperoxide func-
tion (Scheme 1), which was shown to be crucial for
antimalarial activity. The heme-catalyzed cleavage of
Scheme 1. Structures of Fe(III)-heme, quinine and the artemisi-
nin-type drugs examined in the present study.the endoperoxide bridge of artemisinin and formation
of toxic free radicals have received considerable atten-
tion as a likely molecular mechanism for the antimalar-
ial activity of artemisinin and its derivatives [13]. For-
mation of non-polymerizable alkylated heme
derivatives has been demonstrated in vitro and evi-
dence has been provided that C-centered radicals de-
rived from artemisinin act as alkylating agents [14, 15].
Furthermore, it has been shown that covalent artemisi-
nin-heme adducts mimick heme in binding to the
enzyme histidine-rich protein II and as such have the
ability to inhibit heme polymerization [16]. Recently,
evidence has been obtained that iron-activated artemisi-
nin-type drugs act by alkylating an essential enzyme of
Plasmodium falciparum, i.e., a sarco/endoplasmic reticu-
lum Ca2-ATPase ortholog [17].
Formation of a relatively stable noncovalent complex
between antimalarial drugs of the artemisinin-type and
Fe(II)-heme can be regarded as the first step in covalent
interaction, since Fe2 is required for activation of
artemisinin derivatives, i.e., generation of alkyl radicals
[17, 18]. Experimental evidence using spectrophotome-
try has demonstrated that noncovalent interaction in-
deed occurs prior to covalent association in in vitro
experiments [19]. A theoretical model based on a com-
bination of molecular docking and a three-dimensional
quantitative structure-activity study, developed by
Cheng et al. [20], revealed a good correlation between
antimalarial activity and the binding energy of artemisi-
nin derivatives with Fe(II)-heme. The global energy-
minimum configuration of the artemisinin type drug-
heme complex indicates that the endoperoxide bridge
of the drug molecule exactly points towards the Fe ion
of heme and the two carboxyl ethyl groups in heme are
perpendicular to the porphyrin ring, their carboxyl
groups interacting with the hydrogens attached to the
C1 and C9 carbons (Scheme 1) of the artemisinin
derivatives (Figure 3 in [20]). The latter study showed
that the electrostatic energy comprises about two thirds
of the total binding energy, which includes also steric
and hydrophobic components. Since the electrostatic
component revealed the same trend of variation (in-
crease or decrease) as the total stabilization energy with
variation of the structure of the artemisinin-type drugs,
it was suggested that the electrostatic component alone
permits evaluation of the stability of the complexes.
The present study deals with the characterization of
noncovalent complexes formed in vitro between Fe(III)-
heme and artemisinin-type drugs as a model system for
the interaction between the latter drugs and Fe(III)-
heme, Fe(II)-heme or Fe(II)-heme-containing proteins,
which may occur in vivo. In order to evaluate the
potential of the drugs to form noncovalent complexes
with Fe(III)-heme and their relative binding strengths,
we resorted to electrospray ionization mass spectro-
metry (ESI-MS) and collision-induced dissociation tan-
dem mass spectrometry (ESI-MS/CID/MS). Electro-
spray ionization mass spectrometry provides a rapid,
sensitive and highly selective tool for probing noncova-
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this approach rely on the ability of ESI to transfer
noncovalent solution-phase assemblies intact into the
gas phase. The validity of this strategy has been sup-
ported in numerous studies, especially for experiments
on protein-protein and protein-ligand interactions (for a
review, see [25]), including studies on heme-containing
proteins [26]. The relative binding strengths between
the drugs and Fe(III)-heme was assessed using low-
energy collision-induced dissociation. This approach
has previously been shown to be useful in determining
the structure-activity relationship of antimalarial
agents, namely, terpene isonitriles [27] and neocrypto-
lepine derivatives [28]. We demonstrate in the present
work that artemisinin-type drugs form a noncovalent
complex with Fe(III)-heme in vitro, which is weaker
than that with quinine. However, in contrast to quinine
a complex with the dimeric form of Fe(III)-heme or
-hematin could not be detected. Dihydroartemisinin,
the active metabolite of artemisinin derivatives in vivo
[1], is shown to form a second more stable complex in
which a hydrogen is replaced by a sodium atom, which
has a binding strength comparable with that of the
quinine-heme complex.
Experimental
Materials
Hemin (i.e., Fe(III)protoporphyrin IX chloride, purity
98%) was obtained from Fluka (Buchs, Switzerland),
and quinine sulfate salt (purity, 90%) was purchased
from Sigma (St. Louis, MO). Artemisinin and its deriv-
atives, dihydroartemisinin, - and -artemether, and
-arteether, were a gift from Dafra Pharma (Oud-
Turnhout, Belgium). The tested artemisinin-type drugs
had a purity 99%. The structures of Fe(III)-heme
(hereafter, referred to as heme), quinine and the arte-
misinin-type drugs investigated in this study are pre-
sented in Scheme 1. Methanol (super grade) was pur-
chased from Lab-Scan (Dublin, Ireland).
Abbreviations: FP, heme or Fe(III)protoporphyrin
IX (cationic mass, 616 Da); An, artemisinin (MW 282);
DHAn, dihydroartemisinin (MW 284); - and -Am, -
and -isomers of artemether, respectively (MW 298);
Ae, -arteether (MW 312); Qn, quinine (MW 324).
Sample Preparation
Stock solutions of heme were prepared using hemin
and contained 5 mM in MeOH (plus a drop of NH4OH
to solubilize heme), while those of quinine, artemisinin,
and its derivatives, dihydroartemisinin, artemether,
and arteether, contained 5 mM of the drug in MeOH:
CH2Cl2 (19:1; vol/vol). Mixtures of the drugs with
heme were prepared in MeOH with different drug:
heme concentration ratios starting from the stock solu-
tions. In the final solutions, water was added in order to
ensure the stabilization of the ESI process. The final pHof the solutions was about 7, at which the iron atom in
the heme molecule is known to be in the Fe(III) state
[27]. Drug-heme mixtures with a molar concentration
ratio 1:1 contained 250 M drug and 250 M heme in
MeOH:H2O (3:1; vol/vol); for the drug-heme mixtures
with a concentration ratio 1:2 the concentration of the
drug was 125 M, while that of heme was 250 M in
MeOH:H2O (3:1; vol/vol). For the three-component
mixtures (drug 1/drug 2/heme), mixtures were pre-
pared with several concentration molar ratios, i.e., 1:1:1
(125 M of drug 1, 125 M of drug 2, 125 M heme in
MeOH:H2O (3:1; vol/vol)), 1:1:2 (125 M of drug 1, 125
M of drug 2250 M heme in MeOH:H2O (3:1; vol/
vol)) and 1:1:4 (125 M of drug 1, 125 M of drug 2500
M heme in MeOH:H2O (3:1; vol/vol)). The final mix-
tures were subjected to electrospray ionization mass
spectrometry or to collision-induced dissociation tan-
dem mass spectrometry.
Mass Spectrometry
The mass spectral data were obtained in the positive ion
mode on an Autospec-oa-TOF mass spectrometer (Mi-
cromass, Manchester, UK), which was equipped with
an electrospray ionization source. The electrospray ion-
ization source was operated at 4 kV, while the electro-
spray needle was operated at a maximum voltage of 3
kV (i.e., relative to the pepper pot counter electrode
which is at 5 kV). Nitrogen was used both as bath gas
(100 °C; 250 L/h) and as nebulizing gas (15 L/h).
First-order ESI mass spectra were recorded in the mass
range m/z 100–1600. The drug-heme solutions were
introduced into the mass spectrometer by a syringe
pump (Harvard Apparatus, South Natick, MA), em-
ploying a 100 L syringe, at a constant flow rate of 5
L/min. The effect of the cone voltage on the intensity
of the signal of the drug-heme complexes was exam-
ined. Low- and high-energy collision-induced dissocia-
tion (CID) spectra were acquired at a collision energy
(Elab) of 400 eV using He and Xe, respectively, as
collision gas. Helium or xenon was introduced into the
collision cell until the signal of the very weak [FP:
CH3OH]
 complex (m/z 648) reached about 80% of its
original value. In order to ensure reproducible results
the setting of the collision cell gas pressure was not
changed during our experiments. Data acquisition and
processing were performed using OPUS V3.1X soft-
ware. All scans were acquired in the continuum mode.
Results and Discussion
Optimization of ESI Conditions for Detection
of Noncovalent Complexes Between
Artemisinin-Type Drugs and Heme
In a first series of experiments, we recorded first-order
ESI mass spectra of heme, the drugs and binary drug-
heme mixtures and optimized the ESI conditions. In
particular, we noted that the potential on the first
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reduce in-source fragmentation of heme (m/z 616),
which was evident from the formation of an ion at m/z
557 due to loss of the ethylcarboxyl side chain (Figure
1). The loss of a CH2-COOH radical (59 u) is consistent
with the structure of Fe(III)-heme, shown in Scheme 1.
The same procedure was performed for the binary
drug-heme mixtures. Gradual variation of the cone
voltage allowed the establishment of an optimal value
of 75 V at which the signals of the drug-heme com-
plexes were the highest and fragmentation was the
lowest. Optimization of the needle voltage was also
performed because it was found that the dihydroarte-
misinin-heme complex is susceptible to reduction. Ox-
idation-reduction processes are known to occur during
electrospray ionization and have been well documented
(for a review, see [29]). At high needle voltage (2.5
kV), the isotopic cluster of the dihydroartemisinin-
heme complex ([DHAn:FP] m/z 900) was severely
distorted by a hydrogenated species, which corre-
sponds to [DHAn:FP  H] (m/z 901) containing pro-
tonated Fe(II)-heme. It is worth mentioning that proton-
ated Fe(II)-heme (m/z 617) has also been reported for
electrospray ionization of the complex between heme
and cytochrome c [26]. Gradual variation of the needle
voltage, employing a dihydroartemisinin-quinine-heme
mixture (1:1:1), allowed the establishment of an optimal
value of 2.3 kV for the signal intensity of the dihydro-
artemisinin-heme complex without affecting the isoto-
pic pattern as well as for the signal intensity of the
quinine-heme complex.
Using these optimized conditions, first-order ESI
mass spectra were obtained for drug-heme binary mix-
tures (1:2). In order to allow the detailed interpretation
of the spectra, we also recorded the spectrum of heme.
Figure 1a and b show the ESI spectra obtained for heme
under non-optimal and optimal conditions, respec-
tively. Under optimal conditions, the following ions can
be noted in the spectrum of heme: FP (m/z 616),
[FP:MeOH] (m/z 648), [2FP  H] (m/z 1231), [FP:
Figure 1. ESI mass spectra obtained for Fe(III)-heme in MeOH:
H2O (3:1, vol/vol) at (a) non-optimal cone voltage, 150 V, and (b)
optimal cone voltage, 75 V. The needle voltage was 2.3 kV.FPOH] (m/z 1249) and [2FP  2H  Na] (m/z 1253).
The formation of heme dimer-related ions (i.e., [2FP 
H] and [2FP 2HNa]) is worth noting. Their basic
structures likely correspond to that of the dimer units of
-hematin or hemozoin. The ion at m/z 1249, corre-
sponding to [FP:FPOH], can be regarded as a nonco-
valent complex between heme and hematin (i.e.,
Fe(III)protoporphyrin IX hydroxide).
Quinine-heme mixture. Before examining the artemisi-
nin-type drugs, we first examined quinine which is
known to bind to heme [5–7]. Figure 2a illustrates the
ESI mass spectrum obtained for the quinine-heme (1:2)
mixture. Formation of a quinine-heme noncovalent
complex is evident from the intense peak [Qn:FP] (m/z
940, RA 97%). In addition, a complex of quinine with
the heme dimer [(2FP  H):Qn] (m/z 1556, RA 10%)
can be noted. Formation of a noncovalent complex with
heme dimer or -hematin has been detected previously
for neocryptolepine [28]. Peaks related to heme,
namely, [FP] (m/z 616, RA 6%), [FP:MeOH] (m/z 648,
RA 18%), [2FP  H] (m/z 1231, RA 7%), [2FP  2H 
Na] (m/z 1253, RA 11%), and quinine [QnH] (m/z 325,
RA 100%) are also present.
Artemisinin-heme mixture. The ESI mass spectrum ob-
tained for the artemisinin-heme (1:2) mixture is shown
in Figure 2b. The artemisinin-heme noncovalent com-
plex [An:FP] (m/z 898) is the most abundant ion in the
spectrum. It is interesting to note that the artemisinin-
heme complex is stable upon electrospray ionization.
One could expect that artemisinin which contains a
labile endoperoxide bridge would give rise to radical
formation in electrospray ionization, but apparently
this is not the case. In contrast to quinine, a complex of
artemisinin with the heme dimer could not be detected.
The other peaks in the spectrum could easily be attrib-
uted to ions characteristic of the individual components
of the mixture, i.e., [An  H] (m/z 283, RA 61%), [An
 NH ] (m/z 300, RA 98%), [2An  NH ] (m/z 582,
Figure 2. ESI mass spectra of two-component mixtures: (a)
quinine-heme (1:2), (b) artemisinin-heme (1:2), and (c) dihydroar-
temisinin-heme (1:2).4 4
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RA 62%), [2FP  H] (m/z 1231, RA 20%), [2FP  2H 
Na] (m/z 1253, RA 30%). These data provide experi-
mental evidence that artemisinin just as quinine can
form a noncovalent complex with heme in solution. It is
worth noting that the solution consisted of MeOH:H2O
in a molar ratio of 3:1 and that even in the presence of
a relatively high concentration of the organic solvent
methanol an intense peak for the drug-heme complex
could be generated, consistent with the strong electro-
static nature of the drug-heme complex. However, it is
pointed out that there is a distinct difference between
quinine and artemisinin in that quinine also forms a
noncovalent complex with dimeric heme, which is
relevant to its underlying molecular mechanism of
action. It has namely been suggested that quinoline-
type drugs such as chloroquinine and quinidine interact
with both the heme monomer and dimer [6], which is in
agreement with our mass spectrometric observations.
Dihydroartemisinin-heme mixture. Dihydroartemisinin
is of particular interest because it is the active metabo-
lite of semi-synthetic derivatives of artemisinin in vivo
[1, 30]. The major peaks of the ESI mass spectrum
obtained for the binary mixture of dihydroartemisinin
with heme (1:2) (Figure 2c) are summarized in Table 1.
The formation of a radicalar molecular ion species for
dihydroartemisinin (i.e. [DHAn], m/z 284) is worth
noting. This [DHAn] ion can be explained by electro-
chemical oxidation in the electrospray needle [29]. Tak-
ing into account that molecular radical formation is not
observed for artemisinin, artemether and arteether, it
can be suggested that an intact 12-hydroxyl group
facilitates radical formation.
The data obtained for dihydroartemisinin (Figure 2c
and Table 1) demonstrate that dihydroartemisinin just
as artemisinin forms a noncovalent complex with heme
[DHAn:FP] (m/z 900). The formation of a noncovalent
dihydroartemisinin-heme complex with 1:1 stoichiom-
etry is in agreement with the study by Messori et al. [19]
which used spectrophotometric determinations. In ad-
dition, dihydroartemisinin also results in a complex
with heme in which a hydrogen is replaced by a sodium
Table 1. Major peaks in the ESI mass spectrum of a
dihydroartemisinin-heme (1:2) mixture
m/z Peak identification RA (%)
284 [DHAn] 22
302 [DHAn  NH4]
 92
307 [DHAn  Na] 38
586 [2DHAn  NH4]
 80
591 [2DHAn  Na] 65
616 [FP] 28
648 [FP:MeOH] 100
900 [DHAn:FP] 75
922 [DHAn:FP  H  Na] 25
1231 [2F]  H] 28
1253 [2FP  2H  Na] 33atom [DHAn:FP  H  Na] (m/z 922), which was not
detected for either quinine or artemisinin. As sodium
ions are ubiquitous in physiological conditions, it is
logical to assume that this complex may be relevant to
in vivo conditions.
Estimation of the Relative Efficiency of Drugs
to Form Drug-Heme Complexes
For estimation of the relative efficiency of the drugs to
form noncovalent complexes with heme, we examined
three-component mixtures containing a reference drug,
the drug to be tested, and heme. In these mixtures two
drugs, the drug to be tested and the reference drug,
competed for heme. Two drugs were selected as refer-
ence drugs, namely, quinine as a well-known and
highly efficient antimalarial drug and artemisinin as the
lead compound of the artemisinin-type series.
Quinine-artemisinin-hememixture. Quinine-artemisinin-
heme three-component mixtures in different molar con-
centration ratio, 1:1:1, 1:1:2 and 1:1:4, were tested (Fig-
ure 3).
In the ESI mass spectra obtained for all these mix-
tures, peaks related to the individual components were
present, i.e., [Qn  H] (m/z 325), [An  H] (m/z 283),
[An  NH4]
 (m/z 300), [2An  NH4]
 (m/z 582),
[FP:MeOH] (m/z 648), and [2FP  2H  Na] (m/z
1253). For the three-component mixtures, the same
types of noncovalent drug-heme complexes were de-
tected as in the experiments with binary mixtures, i.e.,
[Qn:FP] (m/z 940), [(2FP  H):Qn] (m/z 1556) and
[An:FP] (m/z 898).
The general analysis of the spectra allows us to
suggest that quinine binds more efficiently with heme
in comparison with artemisinin, since the abundance of
the quinine-heme complex is higher than the artemisi-
nin-heme complex for all molar ratios tested. At the
same time, certain concentration dependences were
Figure 3. ESI mass spectra of three-component quinine-artemisi-
nin-heme mixtures with molar ratios of (a) 1:1:1, (b) 1:1:2, and (c)
1:1:4.
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heme noncovalent complexes increased with the heme
concentration, for the [Qn:FP] complex, starting at a
RA of 32% and increasing to 40 and 70% ( Figure 3a, b,
c), and, for the [An:FP] complex, starting at a RA of 6%
and increasing to 10 and 40% . Along with this, the
relative abundance of the [An:FP] complex in relation
to that of the [Qn:FP] complex increased from 19 to 25
and 57% with an increase of the heme concentration in
the mixtures. These results indicate that there is a
competition between the two drugs for binding with
heme in solution: under the conditions of a heme
deficit, quinine binds preferentially, while at a heme
molar excess more intense binding of artemisinin be-
comes possible. The efficiency of artemisinin to bind
noncovalently with heme, however, remains lower than
that of quinine even at a four-fold molar excess of heme
in relation to both drugs.
Quinine-dihydroartemisinin-heme mixture. The same ex-
periment as described above was performed with qui-
nine-dihydroartemisinin-heme mixtures (Figure 4).
Noncovalent drug-heme complexes were detected for
[Qn:FP] (m/z 940) with a relatively high abundance
and for [(2FP  H):Qn] (m/z 1556) and [DHAn:FP]
(m/z 900) with a low RA. With the growth of the
concentration of heme in the mixtures (molar ratios
1:1:2 and 1:1:4), the relative intensities of complex peaks
also increased. For the 1:1:2 mixture (Figure 4b) the
ions, corresponding to the quinine complexes with
heme, [Qn:FP] (m/z 940) and [(2FP  H):Qn] (m/z
1556), had a RA of 68 and 11%, respectively, while the
RA of [DHAn:FP] (m/z 900) increased to 8%. A peak of
the sodium-containing complex [DHAn:FPHNa]
(m/z 922), discussed above for the binary DHAn-heme
system (see Figure 2c), appears here with a RA of 3%.
The results obtained for the 1:1:4 mixture (Figure 4c)
show that the intensity of the DHAn complexes with
heme further increased, i.e., [DHAn:FP] (m/z 900, RA
17%) and [DHAn:FP  H  Na] (m/z 922, RA 5%).
Figure 4. ESI mass spectra of three-component quinine-dihydro-
artemisinin-heme mixtures with molar ratios of (a) 1:1:1, (b) 1:1:2,
and (c) 1:1:4.The results obtained for the quinine-dihydroarte-
misinin-heme mixtures demonstrate that quinine is the
most efficient in forming a noncovalent complex with
heme in equimolar mixtures but that with increase of
the heme concentration dihydroartemisinin-heme com-
plex formation also increases. From the comparison of
the results obtained for the three-component mixtures
discussed above, it follows that artemisinin is slightly
more effective than dihydroartemisinin in binding with
heme. In subsequent experiments aimed at evaluating
more in detail the relative efficiency of the various
artemisinin derivatives, we have, therefore, selected
artemisinin as a reference compound.
Artemisinin-dihydroartemesinin-heme, artemisinin--arte-
ether-heme, artemisinin--artemether-heme and artemisinin-
-artemether-heme mixtures. Mixtures with a molar ra-
tio of 1:1:2 were examined, and for all the three-
component mixtures tested, drug-heme complexes
were detected with the artemisinin-heme complex (m/z
898) dominating the spectrum. In Table 2 the compari-
son is shown of the RAs of the drug-heme complexes in
relation to that of artemisinin-heme.
The data obtained for the three-component mixtures
containing artemisinin as a reference compound sug-
gest that artemisinin is favored compared with its
derivatives for complex formation with heme. Dihydro-
artemisinin, the active metabolite formed from artemisi-
nin derivatives in vivo, is distinguished in the set of the
artemisinin derivatives in that it is the only compound
which forms two types of complexes with heme, i.e., the
expected one ([DHAn:FP]) and the corresponding
Na-containing complex (see Table 2). Similar results
were obtained for the three-component mixtures con-
taining quinine as a reference compound, discussed
above. Furthermore, our data reveal that the stereoiso-
mers of artemether have a different efficiency to form a
noncovalent complex with heme, the -isomer being
about a 1.5 times more efficient than the -isomer. This
experimental observation is in agreement with that
derived by a theoretical model based on a combination
of molecular docking and a three-dimensional quanti-
tative structure-activity study [20], which illustrates
that -isomers of artemisinin derivatives are, in general,
more active than the corresponding -isomers.
Although the ESI technique is widely used in studies
Table 2. Relative abundances of drug-heme complexes in
relation to artemisinin-heme observed in the ESI mass spectra of
three-component mixtures (1:1:2)
Noncovalent complex
drug:heme m/z
TA (%)
(N  3)
[An:FP] 898 100
[DHAn:FP] 900 63  1.5%
[DHAn:F]  H  Na] 922 29  2.5%
[-Am:FP] 914 36  2.6%
[-Am:FP] 914 22  1.3%
[AE:FP] 928 22  3.5%
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correspondence between the specific noncovalent com-
plexes formed in solution and gas-phase cluster ions
produced by the ESI technique may be questioned
[31–33]. Concern has been expressed that single mole-
cules present in the solute can be randomly distributed
in the sprayed droplets and can form any possible type
of associate upon desolvation of the droplets. The
patterns of the ESI mass spectra of the drug-heme
mixtures recorded in the present work (Figures 2, 3, and
4) show, that there is a distinct selectivity in complex
formation which must proceed in the initial solution. In
particular, the association with the heme dimer is
characteristic of quinine and is not observed for arte-
misinin derivatives. Among the artemisinin derivatives
that have slight structural differences, only dihydroar-
temisinin forms a complex with heme with inclusion of
a sodium atom. Since dihydroartemisinin is the active
metabolite of artemisinin derivatives [1, 30], it can be
suggested that interaction of dihydroartemisinin with
heme in vivo may involve association with Na, which
is present in all subcellular liquids. This feature is to be
accounted for in the development of models of molec-
ular mechanisms of action of artemisinin-type antima-
larial agents.
Estimation of the Relative Binding Strength
of Drug-Heme Complexes by Low-Energy
Collision-Induced Dissociation
The relative binding strength between the drugs and
heme in the noncovalent complexes was assessed using
low-energy CID. First, metastable decomposition spec-
tra of the drug-heme complexes (not shown) were
obtained, which revealed no elimination of the drug
and indicated that the drug-heme complexes are stable
in the gas phase. Subsequently, CID spectra were ob-
tained at low and high collision energy using He and
Xe, respectively, as collision gas. The reproducibility of
the CID conditions was evaluated by monitoring the
decomposition of the weakly bound associate of heme
with the solvent molecule methanol, i.e., [FP:MeOH]
(m/z 648):
[FP;MeOH] 3 FPMeOH (1)
The RA of the FP product ion in the CID mass
spectra obtained at low collision energy (Ecom  1.8 eV)
with He was about 42  2% (N  20) of that of the
precursor [FP:MeOH] selected from any of the studied
systems (Figure 5c). Taking into account that the cone
voltage affects the signal intensity of the [FP:MeOH]
complex, it was also confirmed that it does not decay
spontaneously via Pathway 1. All studied [M:FP]
complexes (where M denotes the drug molecule) de-
composed under CID through the neutral loss of the
noncovalently bound drug molecule:[M:FP] 3 FP M (2)
The CID efficiency of the drug-heme complexes did
not depend on the source of a particular complex in that
it was practically the same for [M:FP] ions selected in
experiments using mixtures with different number and
ratio of the interacting components. As could be ex-
pected, a dependence on the collision gas was observed.
Figures 5 and 6 illustrate the CID mass spectra obtained
with He and Xe, respectively, as collision gas, for two
complexes [Qn:FP] (a) and [An:FP] (b). It can be
noted that the RA of the product ion FP is higher for
high-energy CID with Xe. Furthermore, product ions at
lower m/z such as the ion at m/z 557, due to fragmen-
tation of FP, were generated, as could be expected for
high-energy CID. In contrast, low-energy CID with He
only resulted in the elimination of the noncovalently
bound drug molecule and was, therefore, selected in
further experiments aimed at determining the relative
binding strengths of the drug-heme complexes.
Taking into account that DHAn is the only com-
pound among the evaluated artimisinin-type drugs
which forms two types of complexes with heme (Table
2), the CID mass spectrum (Figure 7) was obtained for
Figure 5. Low-energy CID spectra of heme complexes with (a)
quinine, (b) artemisinin, and (c) of the non-specific associate of
heme with methanol. The spectra were obtained with helium as
collision gas at an Elab of 400 eV.
Figure 6. High-energy CID spectra of heme complexes with (a)
quinine and (b) artemisinin. The spectra were obtained with
xenon as collision gas at an E of 400 eV.lab
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the following decomposition was observed:
[DHAn:FP H  Na]
3 [FP H  Na]  DHAn (3)
This low-energy CID experiment thus reveals that
the Na-containing dihydroartemisinin:heme complex
(m/z 922) results in Na-containing heme (m/z 638), in
which the Na atom can be located in one of the two
ethylcarboxyl side chains. It is suggested that during
complex formation the Na atom is transferred from the
sodiated dihydroartemisinin molecule (detected at m/z
307; Table 1), most likely from the 12-hydroxyl group
which is part of a hemiketal function and has acidic
properties.
The relative abundances of the product ions FP or
[FP  H  Na], obtained in low-energy CID of
different drug-heme complexes, averaged using the
data of three to eight independent measurements, are
summarized in Table 3.
The analysis of these data reveals a nearly two-fold
lower CID efficiency of the [Qn:FP] complex in com-
parison with that of all other complexes [M:FP], indi-
cating a higher stability of the quinine-heme complex.
The relative stabilities of all complexes of heme with the
artemisinin-type drugs as determined by CID of the
[M:FP] complexes are comparable within the experi-
mental error. It is interesting to note that the stability of
the [DHAn:FPHNa] complex is as high as that of
the [Qn:FP] complex. The increase of the stability of
the drug-heme complex containing a Na ion can be
Figure 7. Low-energy CID spectra of the Na-containing heme
complex with dihydroartemisinin. The spectrum was obtained
with helium as collision gas at an Elab of 400 eV.
Table 3. Relative abundances and relative standard deviations
of product ions obtained in low-energy CID (He) of different
drug-heme complexes
Complex
RA of product ion, %
FP m/z 616
[Qn:FP] 2.78  0.22 (N5)
[An:FP] 5.6  0.25 (N8)
[DHAn:FP] 5.86  0.35 (N4)
[Am:FP] 5.13  0.26 (N4)
[Am:FP] 4.98  0.44 (N4)
[AE:FP] 5.33  0.31 (N3)
[FP  H  Na] m/z 638
[DHAn:FP  H  Na] 1.93  0.16 (N3)explained by an increased electrostatic interaction,
which has been reported as the main component of
noncovalent interaction in the complex [20]. Since
DHAn is known to be the active metabolite of artemisi-
nin derivatives, it can be suggested that the DHAn-
heme interaction in vivo may also involve sodium ions.
We have stated in the introduction that formation of a
relatively stable noncovalent complex between heme
and drugs of the artemisinin-type can be regarded as
the first step in covalent interaction between the ligand
and heme, since Fe2 is required for activation of
artemisinin derivatives, i.e., generation of alkyl radicals.
In this respect, it has been found experimentally in in
vitro experiments by Messori et al. [19] that the covalent
association is slightly faster for dihydroartemisinin
compared with other artemisinin derivatives, a feature
that could be explained by the initial formation of a
more stable noncovalent heme-dihydroartemisinin
complex.
The comparison of the CID behavior of all drug-
heme complexes with that of [FP:MeOH] (Figure 5c)
shows, that the binding between the components of this
non-specific associate of heme with the solvent mole-
cule methanol is about 10 times weaker than between
the components of specific drug-heme complexes. In
contrast to the ESI-MS data obtained for the - and
-isomers of artemether, indicating that the -isomer is
about 1.5 times more efficient than the -isomer in
binding with heme, the CID data reveal that their
binding strengths are comparable within the experi-
mental error. The reason for this discrepancy may be
due to the fact that solvent effects play a role in
noncovalent complex formation in the bulk solution.
Conclusions
In this study, we have demonstrated, using ESI-MS and
ESI-MS/CID/MS, that stable noncovalent complexes
can be formed between Fe(III)-heme and antimalarial
agents, i.e., quinine, artemisinin, and the artemisinin
derivatives, dihydroartemisinin, - and -artemether,
and -arteether. Differences in the binding behavior of
the examined drugs with Fe(III)-heme and the stability
of the drug-heme complexes were demonstrated. The
results show that all tested antimalarial agents form a
drug-heme complex with a 1:1 stoichiometry but that
quinine also results in a second complex with the heme
dimer or -hematin. ESI-MS experiments performed on
mixtures of the various antimalarial agents with heme
indicate that quinine binds preferentially to Fe(III)-
heme, while ESI-MS/CID/MS shows that the quinine-
heme complex is nearly two times more stable than the
complexes formed between heme and artemisinin and
its derivatives. Moreover, it was found that dihydroar-
temisinin, the active metabolite of the artemisinin-type
drugs in vivo, results in a Na-containing heme-drug
complex, which is as stable as the heme-quinine com-
plex. The efficiency of drug-heme binding of artemisi-
nin derivatives is generally lower and the decomposi-
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these parameters are within the same order of magni-
tude. These results suggest that the efficiency of anti-
malarial agents of the artemisinin-type to form nonco-
valent complexes with Fe(III)-heme is comparable with
that of the traditional antimalarial agent quinine. While
the noncovalent complexes between Fe(III)-heme and
artemisinin, artemether or arteether, were stable in
electrospray ionization conditions, electrochemical re-
actions were observed for the dihydroartemisinin-heme
complex.
Our study illustrates that electrospray ionization
mass spectrometry and collision-induced dissociation
tandem mass spectrometry are suitable tools to probe
noncovalent interactions between heme and antimalar-
ial agents. The results obtained provide insights into the
underlying molecular modes of action of the traditional
antimalarial agent quinine and of the antimalarials of
the artemisinin-type which are currently used to treat
severe or multidrug-resistant malaria.
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